
Fresenius Medical Care
LEI 549300CP8NY40UP89Q40
Upgrade to Premium features
Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market
Get access-
Full access to the largest bond database
Bond parameters,
prospectuses -
Seamless
Data exportAnalyze the data in the most efficient way
-
Bond pricing
Current & historical quotes from 400+ stock exchanges & OTC market
-
Smart risk assessment
Credit ratings, financial reports
Trading Schedule Issuer map
Quotes
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Profile
|
Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services. Its dialysis business is vertically integrated, providing dialysis treatment at its own dialysis clinics and supplying these clinics with a range of products. In addition, the Company sells dialysis products to other dialysis service providers. The Company operates in two business segments: North America and International. The North America segment consists of Renal Therapy Group and Fresenius Medical Services. The International segment consists of Europe and Latin America and one Asia-Pacific unit. During the year ended December 31, 2010, the Company's subsidiary, U.S. Vascular Access Holdings, LLC, completed the acquisition of National Vascular Care Inc.; it acquired a total of 168 existing clinics, and acquired Gambro ABs peritoneal dialysis (PD) business. The Company has a total of 1000 subsidiaries worldwide.
|
General information
-
Organization nameFresenius Medical Care AG&Co
-
Organization statusOperating organization
-
Site
-
IR Site
News
IFRS/US GAAP reports
| 2026 | |
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |









